Status:

NOT_YET_RECRUITING

PK/PD of Vaping THC-containing Liquids vs. Smoked Cannabis

Lead Sponsor:

Roswell Park Cancer Institute

Collaborating Sponsors:

National Institute on Drug Abuse (NIDA)

Conditions:

Cigarette Smoking-Related Carcinoma

Eligibility:

All Genders

21+ years

Phase:

PHASE1

Brief Summary

We will conduct a randomized, within-subjects clinical study to compare short-term pharmacokinetic (PK) and pharmacodynamic (PD) effects of Δ9-tetrahydrocannabinol (THC) vaping liquids vs. smoked cann...

Detailed Description

PRIMARY OBJECTIVE: I. Compare the PK/PD profiles of delta-9 tetrahydrocannabinol (THC) from equivalent standard THC doses (30mg) administered as vaped THC liquid vs. smoked cannabis using a within-su...

Eligibility Criteria

Inclusion

  • Age \>= 21 years of age
  • Report concurrent use of commercial (medical or recreational) smoked cannabis and THC vaping cartridges for at least 3 months prior to enrollment
  • Report smoking cannabis and THC- vaping liquid use at the potency level of the study product at least weekly (4x/month)
  • Report of not currently trying to become pregnant (females). Women of childbearing potential must be willing to provide a urine sample and test negative prior to receiving any study-related products/procedures
  • Willing to complete a THC saliva test to check for recent use (NarcoCheck Ref#:NCE-STHC-1) and semi -quantitative urinary tetrahydrocannabinol-carboxylic acid (THCA) rapid test (NarcoCheck® THC PreDosage) during baseline testing, prior to receiving any study-related products
  • Participant must understand the investigational nature of this study and sign an Institutional Review Board approved written informed consent form prior to receiving any study related procedure

Exclusion

  • • Illegal or non-prescription drug use within the past 90 days. As detected by NacroCheck® Évolutive® (detection in human urine of the 12 most currently abused drugs) at the first session and prior to receiving any study product
  • Report 2 or more drinking occasions/week with 4 or more drinks/occasion
  • Report of daily nicotine use
  • Current or prior diagnosis of any psychotic disorders
  • Current or prior diagnosis of chronic heart conditions
  • Current or prior diagnosis of any respiratory condition
  • Pregnant or currently trying to become pregnant (females)
  • Detection level 4-5 (\>300 ng/mL) from a semi-quantitative urinary THCA rapid test (NarcoCheck® THC PreDosage)
  • Unwilling or unable to follow protocol requirements
  • Any condition which in the Investigator's opinion deems the participant an unsuitable candidate for participation

Key Trial Info

Start Date :

December 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 15 2026

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT06055231

Start Date

December 1 2025

End Date

September 15 2026

Last Update

November 17 2025

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.